Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
Phase 3 – large-scale trial before approval
Conditions:
Biliary Tract Cancer
Sponsor: AstraZeneca AB
trial.available_in:
БГ
Overview
Trial status: Authorised
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Overall survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Description
Progression Free Survival of Rilvegostomig+Chemotherapy vs Durvalumab+Chemotherapy
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 232 participants
Interventions
GEMCITABINE
Drug
IMFINZI 50 mg/mL concentrate for solution for infusion
БГ